- Home
- IR vs MRNA Comparison
IR vs MRNA Comparison
Compare IR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IR | MRNA |
|---|---|---|
| Founded | 1859 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6B | 26.7B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IR | MRNA |
|---|---|---|
| Price | $83.34 | $63.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | ★ $96.00 | $34.27 |
| AVG Volume (30 Days) | 4.3M | ★ 5.1M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.15 | N/A |
| Revenue | $2,375,400,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $7.10 | $9.36 |
| Revenue Next Year | $4.78 | $15.43 |
| P/E Ratio | $73.27 | ★ N/A |
| Revenue Growth | ★ 22.48 | 4.29 |
| 52 Week Low | $68.07 | $22.28 |
| 52 Week High | $100.96 | $85.60 |
Technical Indicators
Market Signals| Indicator | IR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 55.89 |
| Support Level | $77.84 | $45.69 |
| Resistance Level | $83.68 | $85.60 |
| Average True Range (ATR) | 2.76 | 3.65 |
| MACD | -0.60 | 0.93 |
| Stochastic Oscillator | 33.20 | 81.93 |
Price Performance
Historical ComparisonAbout IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.